- Home
- CKPT vs PMO Comparison
CKPT vs PMO Comparison
Compare CKPT & PMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- PMO
- Stock Information
- Founded
- CKPT 2014
- PMO 1993
- Country
- CKPT United States
- PMO United States
- Employees
- CKPT N/A
- PMO N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- PMO Finance Companies
- Sector
- CKPT Health Care
- PMO Finance
- Exchange
- CKPT Nasdaq
- PMO Nasdaq
- Market Cap
- CKPT 335.9M
- PMO 287.4M
- IPO Year
- CKPT 2017
- PMO N/A
- Fundamental
- Price
- CKPT $4.17
- PMO $10.00
- Analyst Decision
- CKPT Buy
- PMO
- Analyst Count
- CKPT 3
- PMO 0
- Target Price
- CKPT $4.33
- PMO N/A
- AVG Volume (30 Days)
- CKPT 1.0M
- PMO 99.0K
- Earning Date
- CKPT 05-16-2025
- PMO 01-01-0001
- Dividend Yield
- CKPT N/A
- PMO 4.10%
- EPS Growth
- CKPT N/A
- PMO N/A
- EPS
- CKPT N/A
- PMO 0.42
- Revenue
- CKPT $41,000.00
- PMO N/A
- Revenue This Year
- CKPT $102,182.93
- PMO N/A
- Revenue Next Year
- CKPT $351.71
- PMO N/A
- P/E Ratio
- CKPT N/A
- PMO $24.38
- Revenue Growth
- CKPT N/A
- PMO N/A
- 52 Week Low
- CKPT $1.47
- PMO $8.57
- 52 Week High
- CKPT $4.50
- PMO $10.68
- Technical
- Relative Strength Index (RSI)
- CKPT 71.99
- PMO 54.55
- Support Level
- CKPT $4.02
- PMO $9.84
- Resistance Level
- CKPT $4.17
- PMO $10.04
- Average True Range (ATR)
- CKPT 0.03
- PMO 0.10
- MACD
- CKPT -0.01
- PMO 0.04
- Stochastic Oscillator
- CKPT 93.33
- PMO 91.30
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.